All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-08-16T10:59:55.000Z

Infection prophylaxis for patients with GvHD

Aug 16, 2024
Share:
Learning objective: After reading this article, learners will be able to describe the latest data relating to GvHD infection prophylaxis and their impact on clinical practice.

Bookmark this article

During the GvHD Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss infection prophylaxis for patients with graft-versus-host disease (GvHD). The discussion was chaired by Professor Mohamad Mohty and featured Frederic Baron, Yi-Bin Chen, Amin Alousi, Florent Malard, Arnon Nagler, Zinaida Peric, and Robert Zeiser.

Infection prophylaxis for patients with GvHD

The steering committee discussed the strategies to manage infections and choices of antibiotics to reduce GvHD-related mortality, the effect of diet on the gut microbiome and GvHD severity, and how to personalize prophylaxis. They also spoke about integration of microbiota therapy into GvHD prophylaxis.

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox